TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36219750

Group type: EXPERIMENTAL
Intervention: Laser 1‐1 J/point (L1J)
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Laser 2‐2 J/point (L2J)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo‐0 J/point
Number of subjects: 158

Group type: EXPERIMENTAL
Intervention: Laser 1‐1 J/point (L1J) and Laser 2‐2 J/point (L2J)
Number of subjects: 158
Study: 33483965

Group type: EXPERIMENTAL
Intervention: Intermittent serial casting in conjunction with occupational therapy and botulinum neurotoxin A (BoNT‐A)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group receiving BoNT‐A and occupational therapy without casting
Number of subjects: 34
Study: 32432556

Group type: EXPERIMENTAL
Intervention: SMS text messaging and consultations for 3 months
Number of subjects: 384

Group type: COMPARATOR
Intervention: Usual care for 3 months
Number of subjects: 384
Study: 36151698

Group type: EXPERIMENTAL
Intervention: Live-in caregivers
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Caregivers with fair or poor sleep quality
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Caregivers with decreased sleep quality
Number of subjects: 47
Study: 34561890

Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin T (hs-cTnT) > 14 ng/l
Number of subjects: 889

Group type: EXPERIMENTAL
Intervention: High-sensitivity cardiac troponin T (hs-cTnT) ≤ 14 ng/l
Number of subjects: 889

Group type: EXPERIMENTAL
Intervention: Lower risk category (ABCD2 score 0-5) with hs-cTnT > URL
Number of subjects: 889

Group type: EXPERIMENTAL
Intervention: Lower risk category (ABCD2 score 0-5) with hs-cTnT ≤ URL
Number of subjects: 889

Group type: EXPERIMENTAL
Intervention: Higher risk category (ABCD2 score 6-7)
Number of subjects: 889
Study: 32556865

Group type: EXPERIMENTAL
Intervention: Artificial Neural Networks (ANNs) model for predicting 1-year progression-free survival (PFS)
Number of subjects: 2890

Group type: EXPERIMENTAL
Intervention: ANNs model for estimating 1-year overall survival (OS)
Number of subjects: 2890

Group type: COMPARATOR
Intervention: High-risk group based on ANNs model scores
Number of subjects: 2890
Study: 35642490

Group type: EXPERIMENTAL
Intervention: Mat Pilates training (3 times a week for 12 weeks)
Number of subjects: 47
Study: 33436709

Group type: EXPERIMENTAL
Intervention: High-salt diet
Number of subjects: 18

Group type: COMPARATOR
Intervention: Low-salt diet
Number of subjects: 18
Study: 32236533

Group type: EXPERIMENTAL
Intervention: Indirect response comparing the patient's condition with that of other patients
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Indirect response describing the patient's deteriorating physiological condition
Number of subjects: 302

Group type: EXPERIMENTAL
Intervention: Redirection to a discussion of the patient's values and goals
Number of subjects: 302

Group type: COMPARATOR
Intervention: Direct response (control)
Number of subjects: 302
Study: 34546341

Group type: EXPERIMENTAL
Intervention: ENHANCE LTC review (intervention period)
Number of subjects: 466

Group type: COMPARATOR
Intervention: Usual LTC reviews (control period)
Number of subjects: 466
Study: 33084829

Group type: EXPERIMENTAL
Intervention: Problematization educational intervention
Number of subjects: 202

Group type: COMPARATOR
Intervention: Conventional monitoring
Number of subjects: 202
Study: 34914128

Group type: EXPERIMENTAL
Intervention: Tripartite intervention (behavioral state modulation + nonnutritive sucking + tucking)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Tripartite intervention
Number of subjects: 64

Group type: COMPARATOR
Intervention: Usual care (control condition)
Number of subjects: 64
Study: 33098889

Group type: EXPERIMENTAL
Intervention: TotalFill BC sealer
Number of subjects: 160

Group type: COMPARATOR
Intervention: AH Plus sealer
Number of subjects: 160
Study: 33302878

Group type: EXPERIMENTAL
Intervention: Preoperative volume replacement therapy (VRT)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Usual care (no VRT)
Number of subjects: 7
Study: 33795096

Group type: EXPERIMENTAL
Intervention: Integrated assessment (contextualizing scenario)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Non-integrated assessment (no integration)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Integrated assessment
Number of subjects: 30
Study: 35713012

Group type: EXPERIMENTAL
Intervention: Grapeseed oil-loaded dermocosmetic nanoemulgel
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo formulation
Number of subjects: 15
Study: 34166970

Group type: EXPERIMENTAL
Intervention: Intensive PCA treatment (3 hours/day, 4 days/week for 2.5 weeks)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Standard PCA treatment (1 hour/day, 3 days/week for 10 weeks)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both IT and ST conditions
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Self-generation of phonological components
Number of subjects: 16
Study: 32228029

Group type: EXPERIMENTAL
Intervention: Dry needling (DN)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Pressure release
Number of subjects: 30
Study: 36215318

Group type: EXPERIMENTAL
Intervention: Patterned 2D ferroelectric perovskite (PMA)2PbCl4 microbelt arrays; flexible photodetectors under 320 nm illumination.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flexible PD with piezo-phototronic effect under external tensile strain of 0.71%.
Number of subjects: 0
Study: 33785069

Group type: EXPERIMENTAL
Intervention: Remifentanil (3 to 4 μg/kg)
Number of subjects: 1150

Group type: COMPARATOR
Intervention: Rapid-onset paralytic agents (succinylcholine or rocuronium 1 mg/kg)
Number of subjects: 1150
Study: 32390164

Group type: EXPERIMENTAL
Intervention: Thiamidol applied four times daily
Number of subjects: 117

Group type: COMPARATOR
Intervention: Thiamidol applied two times daily
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Typical face care regimen containing Thiamidol (day care SPF 30 in the morning, serum and night care in the evening)
Number of subjects: 117
Study: 34850647

Group type: EXPERIMENTAL
Intervention: Bilastine 10 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33357604

Group type: EXPERIMENTAL
Intervention: Distress Tolerance Intervention (DTI)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Healthy Video Control (HVC)
Number of subjects: 60
Study: 32956479

Group type: EXPERIMENTAL
Intervention: Cyclopentolate 1% as spray
Number of subjects: 61

Group type: COMPARATOR
Intervention: Cyclopentolate 1% as drops
Number of subjects: 61
Study: 34871469

Group type: EXPERIMENTAL
Intervention: Personality Disorder Cluster A
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Personality Disorder Cluster B
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Personality Disorder Cluster C
Number of subjects: 94
Study: 32737814

Group type: EXPERIMENTAL
Intervention: Impression Management (IM) scores among males
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: NORC DSM-IV screen for gambling problems (NODS)
Number of subjects: 321

Group type: EXPERIMENTAL
Intervention: Gambling Symptom Assessment Scale (G-SAS) scores
Number of subjects: 321
Study: 32861496

Group type: EXPERIMENTAL
Intervention: Enrofloxacin (ENR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tulathromycin (TUL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (CTL)
Number of subjects: 0
Study: 34608048

Group type: EXPERIMENTAL
Intervention: Supervised 8- to 12-week physical exercise program
Number of subjects: 20

Group type: COMPARATOR
Intervention: Usual physical activity
Number of subjects: 20
Study: 35915198

Group type: EXPERIMENTAL
Intervention: Abemaciclib 200 mg monotherapy twice daily with a meal
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Abemaciclib 200 mg monotherapy twice daily in a modified fasting state
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Abemaciclib 200 mg monotherapy twice daily without regard to food
Number of subjects: 72

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 72
Study: 33331923

Group type: EXPERIMENTAL
Intervention: WBRT + erlotinib
Number of subjects: 224

Group type: COMPARATOR
Intervention: WBRT
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: WBRT + erlotinib (EGFR-mutant)
Number of subjects: 224

Group type: COMPARATOR
Intervention: WBRT (EGFR-mutant)
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 224
Study: 36414282

Group type: EXPERIMENTAL
Intervention: Balanced opioid-free anaesthesia (esketamine, dexmedetomidine, sevoflurane)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Sufentanil and sevoflurane (control group)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both groups (OFA and control)
Number of subjects: 120
Study: 34049857

Group type: EXPERIMENTAL
Intervention: Tocilizumab plus prednisone (TCZ/PDN)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo plus prednisone (PBO/PDN)
Number of subjects: 250
Study: 32835560

Group type: EXPERIMENTAL
Intervention: Vitamin E blended highly cross-linked polyethylene (HXLPE) acetabular cup
Number of subjects: 199

Group type: COMPARATOR
Intervention: Uncemented UHMWPE monoblock cup
Number of subjects: 199
Study: 36544322

Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (a‐tDCS)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Cognitive training
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Anodal tDCS plus cognitive training
Number of subjects: 80

Group type: COMPARATOR
Intervention: Sham
Number of subjects: 80
Study: 34696998

Group type: EXPERIMENTAL
Intervention: Micro-osteoperforation (MOP)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control (no MOP)
Number of subjects: 25
Study: 34533383

Group type: EXPERIMENTAL
Intervention: Social media engagement in longitudinal research
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group-based adolescent substance use intervention
Number of subjects: 0
Study: 34368848

Group type: EXPERIMENTAL
Intervention: Protocol 2008-2015
Number of subjects: 1231

Group type: COMPARATOR
Intervention: Protocol 2000-2007
Number of subjects: 1231

Group type: EXPERIMENTAL
Intervention: Both protocols
Number of subjects: 1231
Study: 34880615

Group type: EXPERIMENTAL
Intervention: Esketamine nasal spray plus newly initiated antidepressant
Number of subjects: 565

Group type: COMPARATOR
Intervention: Antidepressant plus placebo
Number of subjects: 565

Group type: EXPERIMENTAL
Intervention: Esketamine nasal spray
Number of subjects: 565

Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 565
Study: 32888115

Group type: EXPERIMENTAL
Intervention: Ion-releasing coating material
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control material (non-active group)
Number of subjects: 28
Study: 32021143

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) 18/9.6 µg
Number of subjects: 466

Group type: COMPARATOR
Intervention: Placebo MDI
Number of subjects: 466
Study: 35060417

Group type: EXPERIMENTAL
Intervention: Melatonin (6 mg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 33325785

Group type: EXPERIMENTAL
Intervention: Adjuvanted Escherichia coli adhesin vaccine
Number of subjects: 67
Study: 33063220

Group type: EXPERIMENTAL
Intervention: Indirect pulp treatment (IPT)
Number of subjects: 67

Group type: COMPARATOR
Intervention: iRoot BP Plus pulpotomy
Number of subjects: 67
Study: 35643392

Group type: EXPERIMENTAL
Intervention: Nociception Level (NOL) index
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mean Arterial Pressure (MAP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Heart Rate (HR)
Number of subjects: 0
Study: 33507550

Group type: EXPERIMENTAL
Intervention: 75 g glucose drink
Number of subjects: 0

Group type: COMPARATOR
Intervention: Equivalent volume of water (control)
Number of subjects: 0
Study: 32020725

Group type: EXPERIMENTAL
Intervention: Adolescent report of quality of life (PedsQL score 79.1)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Parental report of quality of life (PedsQL score 80.2)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Parental report
Number of subjects: 102

Group type: COMPARATOR
Intervention: Parental report on 'pain and hurt' domain
Number of subjects: 102

Group type: COMPARATOR
Intervention: Parental report on 'social communication' domain
Number of subjects: 102

Group type: COMPARATOR
Intervention: Parental report of total PedsQL scores in male adolescents
Number of subjects: 102

Group type: COMPARATOR
Intervention: Parental report of total PedsQL scores in female adolescents
Number of subjects: 102
Study: 33591484

Group type: EXPERIMENTAL
Intervention: FamilyTalk educational tool
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Pathogenic or likely pathogenic (P/LP) results
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Variant of uncertain significance (VUS) results
Number of subjects: 208
Study: 32449228

Group type: EXPERIMENTAL
Intervention: Mommy go protocol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional support (Control)
Number of subjects: 0
Study: 36085211

Group type: EXPERIMENTAL
Intervention: Active DCP
Number of subjects: 761

Group type: COMPARATOR
Intervention: Passive DCP
Number of subjects: 761
Study: 33351120

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 114

Group type: COMPARATOR
Intervention: Standard anticoagulants
Number of subjects: 114
Study: 34563429

Group type: EXPERIMENTAL
Intervention: Benefit-Finding Therapeutic (BFT) intervention
Number of subjects: 129

Group type: COMPARATOR
Intervention: Simplified psychoeducation
Number of subjects: 129

Group type: COMPARATOR
Intervention: Standard psychoeducation
Number of subjects: 129
Study: 34664858

Group type: EXPERIMENTAL
Intervention: Neurofeedback combined with acupuncture treatment
Number of subjects: 44

Group type: COMPARATOR
Intervention: Acupuncture treatment
Number of subjects: 44
Study: 35929983

Group type: EXPERIMENTAL
Intervention: Active cryoneurolysis
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 60
Study: 34514678

Group type: EXPERIMENTAL
Intervention: PEG‐IFN‐? monotherapy
Number of subjects: 651

Group type: EXPERIMENTAL
Intervention: PEG‐IFN‐? plus NA de novo combination
Number of subjects: 651

Group type: COMPARATOR
Intervention: PEG‐IFN‐? add‐on to NA
Number of subjects: 651

Group type: COMPARATOR
Intervention: NA monotherapy
Number of subjects: 651

Group type: EXPERIMENTAL
Intervention: Overall flares
Number of subjects: 651
Study: 35671649

Group type: EXPERIMENTAL
Intervention: Low-dose methotrexate (LD-MTX)
Number of subjects: 1429
Study: 32825996

Group type: EXPERIMENTAL
Intervention: Dry needling (DN)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham dry needling (Control)
Number of subjects: 30
Study: 34268633

Group type: EXPERIMENTAL
Intervention: Virtual Standardized Patients (VSPs) training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: VSP training
Number of subjects: 0
Study: 32432553

Group type: EXPERIMENTAL
Intervention: Tablet intervention consisting of information about IPV and safety behaviors during prenatal care.
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Tablet intervention (video to promote safety behaviors delivered on a tablet).
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Tablet intervention.
Number of subjects: 9
Study: 35031147

Group type: EXPERIMENTAL
Intervention: Intradermal administration using Immucise™
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard subcutaneous (SC) administration of seasonal influenza vaccine
Number of subjects: 0
Study: 34690144

Group type: COMPARATOR
Intervention: Memantine 20 mg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Memantine 10 mg bid (24-week unblinded active-dose therapeutic trial)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 35560363

Group type: EXPERIMENTAL
Intervention: mnemoPQQ® (21.5 mg/day)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 33231105

Group type: EXPERIMENTAL
Intervention: Combination doses of ketamine and dexmedetomidine, given intranasally
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Optimal combination therapy
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Proposed trial design
Number of subjects: 410

Group type: EXPERIMENTAL
Intervention: Bayesian predictive power of the trial
Number of subjects: 410

Group type: COMPARATOR
Intervention: Comparative effectiveness analysis
Number of subjects: 410
Study: 32569125

Group type: EXPERIMENTAL
Intervention: NBAC
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: BAC
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: All supplements
Number of subjects: 30

Group type: COMPARATOR
Intervention: PLA
Number of subjects: 30
Study: 32563171

Group type: EXPERIMENTAL
Intervention: Perampanel (up to 8 mg/day during double-blind phase, up to 12 mg/day during open-label extension phase)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 163
Study: 35914215

Group type: EXPERIMENTAL
Intervention: Remote patient monitoring with health coaching (n=188)
Number of subjects: 375

Group type: COMPARATOR
Intervention: Wait-list usual care (n=187)
Number of subjects: 375
Study: 34183012

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg once daily
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study: 34014298

Group type: EXPERIMENTAL
Intervention: Phase 3 clinical trials including patients with brain metastases
Number of subjects: 0

Group type: COMPARATOR
Intervention: Phase 3 clinical trials not including patients with brain metastases
Number of subjects: 0
Study: 35045098

Group type: EXPERIMENTAL
Intervention: 12% carbohydrate beverage (250 ml bolus containing 30 g maltodextrin and 30 g sucrose)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 12% carbohydrate beverage
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 15
Study: 34435273

Group type: EXPERIMENTAL
Intervention: 100% of the individual anaerobic threshold (IANS)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 80% of the IANS
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 80% of the IANS with blood flow restriction (BFR)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Low-intensity (LI) without BFR
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Low-intensity blood flow restriction (LI-BFR)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: All training interventions
Number of subjects: 18
Study: 32964458

Group type: EXPERIMENTAL
Intervention: 2-h educational programme about preeclampsia with self-monitoring of blood pressure and urine protein and routine care
Number of subjects: 113

Group type: COMPARATOR
Intervention: 2-h educational programme relevant to urinary tract infection and routine care
Number of subjects: 113
Study: 34704700

Group type: EXPERIMENTAL
Intervention: Er:YAG laser
Number of subjects: 28

Group type: COMPARATOR
Intervention: Traditional scalpel
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 28
Study: 33041442

Group type: EXPERIMENTAL
Intervention: Intravenous Abciximab
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intracoronary saline flush
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 50
Study: 35314635

Group type: EXPERIMENTAL
Intervention: Standardized 4-b-value DW-MRI (b = 0/100/600/800 s/mm2)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Two-b-value ADC calculations (0/600 or 0/800 s/mm2)
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Alternate metrics ADCfast (b ≤ 100 s/mm2), ADCslow (b ≥ 100 s/mm2), and fp
Number of subjects: 210
Study: 32907375

Group type: EXPERIMENTAL
Intervention: Aquatic high intensity interval training (10 weeks, twice weekly, consisting of 10 one-minute exercise intervals with one-minute rest, achieving ⩾80% of peak heart rate)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 17
Study: 32293519

Group type: EXPERIMENTAL
Intervention: Enhanced and early mobilisation protocol with fitness tracker-based feedback
Number of subjects: 348

Group type: COMPARATOR
Intervention: Control group with standard mobilisation according to hospital standards and fitness tracker with blackened screen
Number of subjects: 348
Study: 36126505

Group type: EXPERIMENTAL
Intervention: Adhesive application after HF surface treatment
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Adhesive application after MEP surface treatment
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Adhesive application in aged condition (180 days + 25,000 thermal cycles)
Number of subjects: 120
Study: 33587824

Group type: EXPERIMENTAL
Intervention: Fitusiran 50 mg
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Fitusiran 80 mg
Number of subjects: 17
Study: 32594779

Group type: EXPERIMENTAL
Intervention: AK‐HER2
Number of subjects: 96

Group type: COMPARATOR
Intervention: trastuzumab
Number of subjects: 96
Study: 34607519

Group type: EXPERIMENTAL
Intervention: Pertuzumab injection (5 mg/kg)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Perjeta® (5 mg/kg)
Number of subjects: 87
Study: 33806150

Group type: EXPERIMENTAL
Intervention: Christian Orthodox fasting (OF)
Number of subjects: 43

Group type: COMPARATOR
Intervention: 16:8 time-restricted eating (TRE)
Number of subjects: 43
Study: 32463456

Group type: EXPERIMENTAL
Intervention: Osimertinib, 80 mg daily and Bevacizumab, 15 mg/kg once every 3 weeks
Number of subjects: 49
Study: 36443896

Group type: EXPERIMENTAL
Intervention: Group-format multi-component programme based on cognitive behavioural therapy and positive psychology (6 sessions, 10 weeks)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 64
Study: 32917417

Group type: EXPERIMENTAL
Intervention: Laminaria digitata (LD)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Undaria pinnatifida (UP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control meal (pea protein)
Number of subjects: 20
Study: 34627213

Group type: EXPERIMENTAL
Intervention: Sandwich principle instructional video
Number of subjects: 51

Group type: COMPARATOR
Intervention: Normal instructional video
Number of subjects: 51
Study: 32812644

Group type: EXPERIMENTAL
Intervention: Alcohol screening and brief intervention
Number of subjects: 33
Study: 35475290

Group type: EXPERIMENTAL
Intervention: Regular diet
Number of subjects: 302

Group type: COMPARATOR
Intervention: Restricted diet
Number of subjects: 302
Study: 34135032

Group type: EXPERIMENTAL
Intervention: Data-enabled clinical trials using electronic healthcare records (EHRs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Facilitating patient recruitment for postmarketing authorisation trials
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Improving trial design and execution through EHR-based methods
Number of subjects: 0